250 related articles for article (PubMed ID: 22006669)
1. Current and emerging targeted therapies for metastatic breast cancer.
Perez EA; Spano JP
Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in novel targeted therapies for HER2-positive breast cancer.
Murphy CG; Morris PG
Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
[TBL] [Abstract][Full Text] [Related]
3. Emerging targeted therapies for breast cancer.
Alvarez RH; Valero V; Hortobagyi GN
J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
6. Dual HER2-targeted approaches in HER2-positive breast cancer.
Ahn ER; Vogel CL
Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
[TBL] [Abstract][Full Text] [Related]
7. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
9. The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer.
Conte P; Guarneri V
Clin Breast Cancer; 2012 Jun; 12(3):157-66. PubMed ID: 22607765
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine for metastatic breast cancer.
Chen TW; Bedard PL
Curr Opin Oncol; 2013 Nov; 25(6):615-24. PubMed ID: 24097103
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies in breast cancer: where are we now?
Di Cosimo S; Baselga J
Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
[TBL] [Abstract][Full Text] [Related]
12. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
Zelnak AB; Wisinski KB
Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives.
El Saghir NS; Tfayli A; Hatoum HA; Nachef Z; Dinh P; Awada A
Crit Rev Oncol Hematol; 2011 Dec; 80(3):433-49. PubMed ID: 21330148
[TBL] [Abstract][Full Text] [Related]
14. Personalizing therapy for metastatic breast cancer.
Morris PG; Hudis CA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1223-6. PubMed ID: 19761426
[TBL] [Abstract][Full Text] [Related]
15. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
17. An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H
Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
[TBL] [Abstract][Full Text] [Related]
18. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in early-stage breast cancer: achievements and promises.
Sledge GW; Jotwani AC; Mina L
Surg Oncol Clin N Am; 2010 Jul; 19(3):669-79. PubMed ID: 20620934
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.
Petrelli F; Cabiddu M; Cazzaniga ME; Cremonesi M; Barni S
Oncologist; 2008 Apr; 13(4):373-81. PubMed ID: 18448551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]